1248-P: Glycemic Trend in Metropolitan vs. Nonmetropolitan Cities of India-Two-Year Results of LANDMARC
Authors: UNNIKRISHNAN AMBIKA GOPALAKRISHNAN , DAS ASHOK K. , JOSHI SHASHANK , MITHAL AMBRISH , KALRA SANJAY , KUMAR K.M. PRASANNA , THACKER HEMANT , SETHI BIPIN , CHOWDHURY SUBHANKAR , NAIR ARJUN , MOHANASUNDARAM SENTHILNATHAN , MENON SHALINI K. , SALVI VAIBHAV , CHODANKAR DEEPA , TRIVEDI CHIRAG , WANGNOO SUBHASH KUMAR , ZARGAR ABDUL H. , RAIS NADEEM 
Published: May 2022

Glycemic trends of T2D from metropolitan and non-metropolitan cities of India have been less studied and hence, were evaluated during the second year of LANDMARC trial (a 3-year nationwide prospective observational study; CTRI/2017/05/008452) . A total of 5318 of 6234 evaluable participants with T2D taking ≥2 antihyperglycemic medications (with/without glycemic control) completed 2-year follow-up visit. The age, T2D duration, baseline A1C were comparable across participants from metropolitan and non-metropolitan cities. At 2-year, a decrease in all glycemic parameters was noted. There was a noticeable improvement in A1C levels from baseline in participants from metropolitan and non-metropolitan cities (mean [95% CI]: −0.5% [−0.6, −0.4] and −0.7% [−0.8, −0.6]; p=0.0450, respectively) . Almost, one-third of the participants in metropolitan (491/16[30.6%]) and non-metropolitan (806/2280 [35.4%]) cities achieved glycemic control (A1C &lt;7%) . No significant difference in change from baseline between metropolitan and non-metropolitan cities was noted for FPG (p=0.3408) and PPG (p=0.6890) (Table) . Overall, participants from both metropolitan and non-metropolitan cities showed marked improvement in all glycemic parameters from baseline to the end of 2 years. These results help compare the longitudinal glycemic patterns among participants with T2D in cities across India.

Disclosure

A. Unnikrishnan: Advisory Panel; Intas Pharmaceuticals Ltd. Speaker's Bureau; Abbott, AstraZeneca, Boehringer-Ingelheim, Sanofi. Other Relationship; Novo Nordisk, Serdia Pharmaceuticals (India) Pvt. Ltd., Torrent Pharmaceuticals Ltd. A.K. Das: Advisory Panel; Boehringer Ingelheim International GmbH, Novo Nordisk, Roche Diagnostics, Sanofi. Speaker's Bureau; Dr. Reddy’s Laboratories Ltd., Lupin Pharmaceuticals, Inc., USV Private Limited. S. Joshi: Advisory Panel; Abbott, Boehringer Ingelheim International GmbH, Dr. Reddy’s Laboratories Ltd., Eli Lilly and Company, Novo Nordisk, Roche Diabetes Care. Consultant; Biocon, Glenmark Pharmaceuticals, Sanofi, USV Private Limited. A. Mithal: Advisory Panel; Eris Lifesciences Ltd. Consultant; Glenmark Pharmaceuticals, Lupin Pharmaceuticals, Inc., USV Private Limited. Speaker's Bureau; Abbott Diabetes, AstraZeneca, Biocon, Boehringer Ingelheim International GmbH, Dr. Reddy’s Laboratories Ltd., Novartis AG, Novo Nordisk, Sanofi. S. Kalra: Speaker's Bureau; Boehringer Ingelheim International GmbH, Novo Nordisk A/S, Sanofi. K. Kumar: None. H. Thacker: None. B. Sethi: None. S. Chowdhury: None. A. Nair: None. S. Mohanasundaram: Employee; Sanofi. V. Salvi: Employee; Sanofi. D. Chodankar: Employee; Sanofi. C. Trivedi: None. S. Wangnoo: None. A.H. Zargar: Advisory Panel; Sanofi. Speaker's Bureau; AstraZeneca, Biocon, Boehringer Ingelheim International GmbH, Intas Pharmaceuticals Ltd., Janssen Pharmaceuticals, Inc., Lupin Pharmaceuticals, Inc., Novo Nordisk, USV Private Limited. N. Rais: None.

Funding

Sanofi, India